Pre-made Tebotelimab benchmark antibody ( Bispecific scFv with Crossover, anti-PDCD1/PD-1;LAG3 therapeutic antibody, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD223 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tebotelimab biosimilar, Bispecific scFv with Crossover, Anti-PDCD1/PD-1;LAG3 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tebotelimab (MGD013) is a bispecific monoclonal antibody. It is anticipated that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-556-1mg	1mg	Inquiry
GMP-Bios-ab-556-10mg	10mg	Inquiry
GMP-Bios-ab-556-100mg	100mg	Inquiry
GMP-Bios-ab-556-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tebotelimab biosimilar, Bispecific scFv with Crossover, Anti-PDCD1/PD-1;LAG3 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD223 therapeutic antibody
INN Name	Tebotelimab
Target	PD-1;LAG3
Format	Bispecific scFv with Crossover
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2019
Year Recommended	2020
Companies	MacroGenics
Conditions Approved	na
Conditions Active	Gastic cancer;Oesophageal cancer;Head and neck cancer;Cholangiocarcinoma;Liver cancer;Haematological malignancies;Malignant melanoma;Solid tumours
Conditions Discontinued	na
Development Tech	na